High Myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas

International Journal of Cancer

Volumn 131, Issue 4, 2012, Pages

  Schrader, Alexandra ^a,b   Bentink, Stefan ^c,d   Spang, Rainer ^c,d   Lenze, Dido ^d,e   Hummel, Michael ^d,e   Kuo, Michael ^f   Arrand, John R ^g   Murray, Paul G ^g   Trümper, Lorenz ^a,b,d   Kube, Dieter ^a,b,d   Vockerodt, Martina ^a,d,g  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d Deutsche Krebshilfe   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^g UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

c Myc; gene expression; germinal center B cells; index

Indexed keywords

MYC PROTEIN;

ARTICLE; BURKITT LYMPHOMA; CANCER PROGNOSIS; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE TRANSLOCATION; GENETIC TRANSFECTION; GERMINAL CENTER; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; MICROARRAY ANALYSIS; ONCOGENE MYC; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK FACTOR;

BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA PRIMERS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84862543309     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26423     Document Type: Article

References (49)

1. Stevenson F, Sahota S, Zhu D, Ottensmeier C, Chapman C, Oscier D, Hamblin T,. Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes. Immunol Rev 1998; 162: 247-59. (Pubitemid 28182140)
2. Kuppers R, Klein U, Hansmann ML, Rajewsky K,. Cellular origin of human B-cell lymphomas. N Engl J Med 1999; 341: 1520-9. (Pubitemid 29526356)
3. Klein G,. Specific chromosomal translocations and the genesis of B-cell-derived tumors in mice and men. Cell 1983; 32: 311-15. (Pubitemid 13127811)
4. Magrath I,. The pathogenesis of Burkitt's lymphoma. Adv Cancer Res 1990; 55: 133-270. (Pubitemid 20259302)
5. Joos S, Falk MH, Lichter P, Haluska FG, Henglein B, Lenoir GM, Bornkamm GW,. Variable breakpoints in Burkitt lymphoma cells with chromosomal t(8;14) translocation separate c-myc and the IgH locus up to several hundred kb. Hum Mol Genet 1992; 1: 625-32.
6. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F,. The c-Myc target gene network. Semin Cancer Biol 2006; 16: 253-64. (Pubitemid 44311039)
7. Adhikary S, Eilers M,. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005; 6: 635-45. (Pubitemid 41081267)
8. Eilers M, Eisenman RN,. Myc's broad reach. Genes Dev 2008; 22: 2755-66.
9. Cole MD, Cowling VH,. Transcription-independent functions of MYC: regulation of translation and DNA replication. Nat Rev Mol Cell Biol 2008; 9: 810-15.
10. Wanzel M, Herold S, Eilers M,. Transcriptional repression by Myc. Trends Cell Biol 2003; 13: 146-50. (Pubitemid 36293787)
11. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL,. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318: 533-8. (Pubitemid 16173038)
12. Kovalchuk AL, Qi CF, Torrey TA, Taddesse-Heath L, Feigenbaum L, Park SS, Gerbitz A, Klobeck G, Hoertnagel K, Polack A, Bornkamm GW, Janz S, et al. Burkitt lymphoma in the mouse. J Exp Med 2000; 192: 1183-90.
13. Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R, Valdez R, Palmer SE, Haas SS, Stewart AK, Fonseca R, Kremer R, et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008; 13: 167-80. (Pubitemid 351163163)
14. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM,. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med 1988; 167: 353-71. (Pubitemid 18073641)
15. Zhu D, Qi CF, Morse HC III, Janz S, Stevenson FK,. Deregulated expression of the Myc cellular oncogene drives development of mouse "Burkitt- like" lymphomas from naive B cells. Blood 2005; 105: 2135-7. (Pubitemid 40731803)
16. Truffinet V, Pinaud E, Cogne N, Petit B, Guglielmi L, Cogne M, Denizot Y,. The 3' IgH locus control region is sufficient to deregulate a c-myc transgene and promote mature B cell malignancies with a predominant Burkitt-like phenotype. J Immunol 2007; 179: 6033-42.
17. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC, Hansmann ML, Haralambieva E, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354: 2419-30. (Pubitemid 43855045)
18. Bentink S, Wessendorf S, Schwaenen C, Rosolowski M, Klapper W, Rosenwald A, Ott G, Banham AH, Berger H, Feller AC, Hansmann ML, Hasenclever D, et al. Pathway activation patterns in diffuse large B-cell lymphomas. Leukemia 2008; 22: 1746-54.
19. Kuppers R, Dalla-Favera R,. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 2001; 20: 5580-94. (Pubitemid 32928099)
20. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006; 354: 2431-42. (Pubitemid 43855046)
21. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA Jr, Marks JR, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353-7. (Pubitemid 43128862)
22. Hortnagel K, Mautner J, Strobl LJ, Wolf DA, Christoph B, Geltinger C, Polack A,. The role of immunoglobulin kappa elements in c-myc activation. Oncogene 1995; 10: 1393-401.
23. Ranuncolo SM, Polo JM, Dierov J, Singer M, Kuo T, Greally J, Green R, Carroll M, Melnick A,. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol 2007; 8: 705-14. (Pubitemid 46965346)
24. Lee CH, Melchers M, Wang H, Torrey TA, Slota R, Qi CF, Kim JY, Lugar P, Kong HJ, Farrington L, van der Zouwen B, Zhou JX, et al. Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein. J Exp Med 2006; 203: 63-72. (Pubitemid 43139646)
25. Vockerodt M, Morgan SL, Kuo M, Wei W, Chukwuma MB, Arrand JR, Kube D, Gordon J, Young LS, Woodman CB, Murray PG,. The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin's Reed-Sternberg-like phenotype. J Pathol 2008; 216: 83-92.
26. Klein SC, Kube D, Abts H, Diehl V, Tesch H,. Promotion of IL8, IL10, TNF α and TNF β production by EBV infection. Leuk Res 1996; 20: 633-6. (Pubitemid 26364742)
27. Vockerodt M, Haier B, Buttgereit P, Tesch H, Kube D,. The Epstein-Barr virus latent membrane protein 1 induces interleukin-10 in Burkitt's lymphoma cells but not in Hodgkin's cells involving the p38/SAPK2 pathway. Virology 2001; 280: 183-98. (Pubitemid 34165349)
28. Vockerodt M, Pinkert D, Smola-Hess S, Michels A, Ransohoff RM, Tesch H, Kube D,. The Epstein-Barr virus oncoprotein latent membrane protein 1 induces expression of the chemokine IP-10: importance of mRNA half-life regulation. Int J Cancer 2005; 114: 598-605. (Pubitemid 40349619)
29. Vockerodt M, Tesch H, Kube D,. Epstein-Barr virus latent membrane protein-1 activates CD25 expression in lymphoma cells involving the NFkappaB pathway. Genes Immun 2001; 2: 433-41. (Pubitemid 33674262)
30. Falk MH, Hultner L, Milner A, Gregory CD, Bornkamm GW,. Irradiated fibroblasts protect Burkitt lymphoma cells from apoptosis by a mechanism independent of bcl-2. Int J Cancer 1993; 55: 485-91. (Pubitemid 23300603)
31. Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M,. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 2002; 18 (Suppl 1): S96-S104. (Pubitemid 41185642)
32. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP,. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-64.
33. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP,. Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011; 27: 1739-40.
34. Vrzalikova K, Vockerodt M, Leonard S, Bell A, Wei W, Schrader A, Wright KL, Kube D, Rowe M, Woodman CB, Murray PG,. Downregulation of BLIMP1-α by the EBV oncogene, LMP1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B cell lymphomas. Blood 2011; 117: 9568-77.
35. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP,. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-50. (Pubitemid 41528093)
36. Schlee M, Holzel M, Bernard S, Mailhammer R, Schuhmacher M, Reschke J, Eick D, Marinkovic D, Wirth T, Rosenwald A, Staudt LM, Eilers M, et al. C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma. Int J Cancer 2007; 120: 1387-95. (Pubitemid 46355371)
37. Klapproth K, Sander S, Marinkovic D, Baumann B, Wirth T,. The IKK2/NF-{kappa}B pathway suppresses MYC-induced lymphomagenesis. Blood 2009; 114: 2448-58.
38. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM,. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 2004; 101: 9309-14. (Pubitemid 38812872)
39. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, Horsman DE, Gascoyne RD,. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009; 114: 3533-7.
40. Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, Dyer MJ, Siebert R, Kuruvilla J, Klasa R, Connors JM, Gascoyne RD, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009; 114: 2273-9.
41. Klapper W, Stoecklein H, Zeynalova S, Ott G, Kosari F, Rosenwald A, Loeffler M, Trumper L, Pfreundschuh M, Siebert R,. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia 2008; 22: 2226-9.
42. Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B,. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci USA 2003; 100: 8164-9. (Pubitemid 36842516)
43. Schuhmacher M, Kohlhuber F, Holzel M, Kaiser C, Burtscher H, Jarsch M, Bornkamm GW, Laux G, Polack A, Weidle UH, Eick D,. The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res 2001; 29: 397-406. (Pubitemid 32060926)
44. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, Chan JW, Rosenwald A, Gascoyne RD, Staudt LM,. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 2008; 111: 3701-13.
45. Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, Cattoretti G, Ye BH,. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008; 111: 1515-23. (Pubitemid 351213441)
46. Fan J, Zeller K, Chen YC, Watkins T, Barnes KC, Becker KG, Dang CV, Cheadle C,. Time-dependent c-Myc transactomes mapped by array-based nuclear run-on reveal transcriptional modules in human B cells. PLoS One 2010; 5: e9691.
47. Basso K, Klein U, Niu H, Stolovitzky GA, Tu Y, Califano A, Cattoretti G, Dalla-Favera R,. Tracking CD40 signaling during germinal center development. Blood 2004; 104: 4088-96. (Pubitemid 39620160)
48. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009; 459: 717-21.
49. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, Forman S, Jove R, Pardoll DM, Yu H,. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009; 15: 283-93.